Table 5.
The results of antimicrobial susceptibility profile of 62 Shigella isolates
| Antibiotics | S. flexneri (n = 33) | S. sonnei (n = 15) | S. boydii (n = 14) | Total isolates (n = 62) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sensitive (%) | Intermediate (%) | Resistant (%) | Sensitive (%) | Intermediate (%) | Resistant (%) | Sensitive (%) | Intermediate (%) | Resistant (%) | Sensitive (%) | Intermediate (%) | Resistant (%) | |
| Amikacin (AN/30 μg) | 5 (15.15) | 18 (54.55) | 10 (30.30) | 6 (40) | 7 (46.67) | 2 (13.33) | 8 (57.14) | 2 (14.29) | 4 (28.57) | 19 (30.64) | 27 (43.55) | 16 (25.81) |
| Ampicillin (AMX/25 μg) | 0 (0.0) | 0 (0.0) | 33 (100.0) | 1 (6.67) | 0 (0.0) | 14 (93.33) | 1 (1.14) | 0 (0.0) | 13 (92.86) | 2 (3.22) | 0 (0.0) | 60 (90.78) |
| Azithromycin (AZM/15 μg) | 22 (66.67) | 2 (6.06) | 9 (27.27) | 8 (53.34) | 2 (13.33) | 5 (33.33) | 6 (42.86) | 4 (28.57) | 4 (28.57) | 36 (58.06) | 8 (12.9) | 18 (29.04) |
| Ceftriaxone (CRO/30 μg) | 8 (24.24) | 0 (0.0) | 25 (75.76) | 1 (6.67) | 0 (0.0) | 14 (93.33) | 3 (21.43) | 0 (0.0) | 11 (78.57) | 12 (19.35) | 0 (0.0) | 50 (80.65) |
| Cefotaxime (CTX/30 μg) | 3 (9.09) | 4 (12.12) | 26 (78.79) | 1 (6.67) | 0 (0.0) | 14 (93.33) | 3 (21.43) | 0 (0.0) | 11 (78.57) | 7 (11.29) | 4 (6.45) | 51 (82.26) |
| Ceftazidime (CAZ/30 μg) | 14 (42.42) | 5 (15.15) | 14 (42.43) | 5 (33.33) | 8 (53.34) | 2 (13.33) | 4 (28.57) | 4 (28.57) | 6 (42.86) | 23 (37.1) | 17 (27.42) | 22 (35.48) |
| Ceftizoxime (CT/30 μg) | 6 (18.18) | 5 (15.15) | 22 (66.67) | 4 (26.66) | 4 (26.66) | 7 (46.67) | 4 (28.57) | 1 (7.14) | 9 (64.29) | 14 (22.58) | 10 (16.13) | 38 (61.29) |
| Cefixime (CFM/5 μg) | 8 (24.24) | 0 (0.0) | 25 (75.76) | 1 (6.67) | 0 (0.0) | 14 (93.33) | 1 (1.14) | 0 (0.0) | 13 (92.86) | 10 (16.13) | 0 (0.0) | 52 (83.87) |
| Cefoxitin (FOX/30 μg) | 33 (100) | 0 (0.0) | 0 (0.0) | 14 (93.33) | 0 (0.0) | 1 (6.67) | 8 (57.14) | 1 (7.14) | 5 (35.72) | 55 (88.71) | 1 (1.61) | 6 (9.68) |
| Chloramphenicol (C/30 μg) | 24 (72.73) | 1 (3.03) | 8 (24.24) | 14 (93.33) | 1 (6.67) | 0 (0.0) | 12 (85.72) | 1 (7.14) | 1 (7.14) | 50 (80.64) | 3 (4.84) | 9 (14.52) |
| Ciprofloxacin (CP/5 μg) | 4 (12.12) | 12 (36.36) | 17 (51.52) | 3 (20.0) | 5 (33.33) | 7 (46.67) | 2 (14.29) | 1 (7.14) | 11 (78.57) | 9 (14.52) | 18 (29.04) | 35 (56.45) |
| Nalidixic acid (NA/30 μg) | 14 (42.43) | 13 (39.39) | 6 (18.18) | 6 (40) | 1 (6.67) | 8 (53.34) | 2 (14.29) | 4 (28.57) | 8 (57.14) | 22 (35.48) | 18 (29.04) | 22 (35.48) |
| Norfloxacin (NOR/10 μg) | 33 (100) | 0 (0.0) | 0 (0.0) | 14 (93.33) | 0 (0.0) | 1 (6.67) | 11 (78.57) | 0 (0.0) | 3 (21.43) | 58 (93.55) | 0 (0.0) | 4 (6.45) |
| Ofloxacin (OFX/5 μg) | 30 (90.91) | 3 (9.09) | 0 (0.0) | 11 (73.33) | 3 (20.0) | 1 (6.67) | 11 (78.57) | 1 (7.14) | 2 (14.29) | 52 (83.87) | 7 (11.29) | 3 (4.84) |
| Piperacillin–tazobactam (100/10 μg) | 3 (9.09) | 1 (3.03) | 29 (87.88) | 0 (0.0) | 1 (6.67) | 14 (93.33) | 2 (14.29) | 1 (7.14) | 11 (78.57) | 5 (8.06) | 3 (4.84) | 54 (87.1) |
| Trimethoprim–sulfamethoxazole (SXT/1.25/23.75 μg) | 2 (6.06) | 4 (12.12) | 27 (81.82) | 1 (6.67) | 1 (6.67) | 13 (86.66) | 2 (14.29) | 0 (0.0) | 12 (85.71) | 5 (8.06) | 5 (8.06) | 52 (83.87) |